HeartSciences Inc. (NASDAQ:HSCS) Sees Large Decrease in Short Interest

HeartSciences Inc. (NASDAQ:HSCS) saw a large drop in short interest in September. As of September 15th, there was short interest totaling 39,859 shares, a drop of 65.1% from the August 31st total of 114,152 shares. Currently, 0.9% of the company’s stock are short sold. Based on an average trading volume of 131,326 shares, the days-to-cover ratio is presently 0.3 days.

HeartSciences Trading Up 2.2%

HeartSciences stock traded up $0.10 during mid-day trading on Friday, hitting $4.73. The company had a trading volume of 97,695 shares, compared to its average volume of 146,063. The stock’s 50 day moving average price is $3.01 and its two-hundred day moving average price is $2.50. HeartSciences has a 12 month low of $1.63 and a 12 month high of $5.25. The company has a market capitalization of $22.70 million, a PE ratio of -1.47 and a beta of 1.85.

HeartSciences (NASDAQ:HSCS) last issued its quarterly earnings results on Monday, September 14th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.14). The firm had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.10 million. Equities research analysts anticipate that HeartSciences will post -2.99 EPS for the current year.

Wall Street Analysts Forecast Growth

HSCS has been the topic of several research reports. Wall Street Zen raised shares of HeartSciences from a “sell” rating to a “hold” rating in a research note on Sunday, September 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a research note on Monday, September 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $8.00.

About HeartSciences

HeartSciences, Inc is a medical technology company focused on improving the detection and management of cardiovascular disease. The company develops electrocardiography (ECG) technologies intended to provide clinicians with additional information about cardiac function using a test that is widely available in healthcare settings.

Its principal technology is the MyoVista wavECG system, which applies proprietary signal-processing methods, including wavelet analysis, to standard 12-lead ECG data.